differences from BzRAs, which potentially have clinical benefit. The efficacy of all BzRAs in reducing sleep latency and most BzRAs in increasing total sleep time (TST) is well established, as is their safety. Efficacy for specific sleep maintenance measures is less well studied, but shorter-acting BzRAs have not been shown to consistently reduce wake after sleep onset (WASO) or number of awakenings. Moreover, some BzRAs reduce slow-wave sleep (SWS), a finding with no certain clinical consequence, but SWS has been associated with decreased arousability from sleep. This suggests that increased SWS may have positive effects on overall sleep quality, and drugs that increase SWS may have clinical utility.
In preliminary studies, tiagabine has been shown to improve sleep maintenance and to significantly increase SWS in healthy elderly subjects and adult patients with primary insomnia. [8] [9] [10] The present study evaluated dose-response effects of tiagabine on sleep in a large sample of adult patients with primary insomnia.
METHODS

Study Design and General Methods
A double-blind, parallel-group, dose-response study of tiagabine was conducted in 30 centers in the United States, utilizing an identical research protocol. Four doses of tiagabine (4, 6, 8 , and 10 mg) were compared with placebo in individuals with primary insomnia. Patient selection included a clinical assessment visit and 2 consecutive nights of polysomnography (PSG) with singleblind administration of placebo to ensure all study entry criteria were met. Patients who were randomly assigned to treatment or placebo groups returned for 2 consecutive nights of PSG on the assigned dose of study drug, followed by safety monitoring, prior to study discharge. The protocol was approved by an institutional review board for each center, and the study was performed in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines.
Study Drug
Tiagabine is rapidly absorbed, with a t max of about 45 minutes in the fasting state. 17 The rate, but not the extent, of absorption is reduced when ingested with food. Tiagabine has an elimination half-life of 7 to 9 hours. In the United States, tiagabine is approved as adjunctive therapy for partial seizures, with dose to be titrated starting at 4 mg per day. 17 The maximum recommended daily dose is 56 mg per day for adults taking hepatic enzyme-inducing drugs.
Patient Screening Procedures
Men and women, aged 18 to 64 years, with chronic primary insomnia were eligible for participation in the study. Initial screening was performed via telephone. Prospective subjects, who appeared to meet entry criteria and continued to express interest in participation, were scheduled for a clinical evaluation at the study site. After giving written informed consent, each subject underwent medical, sleep, and psychiatric histories; a physical examination; laboratory tests; and an electrocardiogram. Patients were required to meet the following inclusion and exclusion criteria:
INCLUSION
(1) Diagnosis of primary insomnia according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-criteria 11 , text revision (DSM-IV-TR) (2) Self-reported time to fall asleep of at least 15 minutes, wake time during the night of 60 minutes or longer, and total sleep duration of less than 6 hours, all on at least 3 nights each week during the preceding month (3) Self-report of 6.5 to 9 hours in bed per night, at least 5 nights per week during the preceding month (4) A habitual bedtime at least 5 nights per week of between 9:00 pm and midnight, varying no more than 1 hour.
EXCLUSION
(1) A diagnosis of any DSM-IV-TR axis-1 psychiatric disorder other than primary insomnia (2) Symptoms or signs of any primary sleep disorder other than primary insomnia (3) A history of substance abuse (4) A diagnosis of any disorder that may interfere with study drug pharmacokinetics (5) Performing shift work (6) Traveling across more than 3 time zones in the past 2 weeks (7) Taking any psychotropic medication, any cytochrome P3A4-inducer/inhibitor, or any medication that may affect sleepwake function in the past 2 weeks (8) Napping 3 or more times each week over the preceding month (9) Consuming ≥ 300 mg of xanthines per day (10) Typically consuming more than 14 alcoholic units per week (11) Smoking more than 1 pack of cigarettes per day (12) A body mass index of 34 kg/m 2 or greater (13) Known sensitivity to sedative hypnotics (14) Previously received tiagabine or had received an investigational drug within the last month
PSG Screening
Individuals meeting all clinical entry criteria were scheduled for 2 consecutive nights of PSG with single-blind placebo, administered 30 minutes prior to lights out. The scheduled lightsout time for each patient was within 30 minutes of his or her usual bedtime and was held constant for both screening and treatment PSGs. Time in bed was 480 minutes for all PSG nights. On the first screening night, patients were evaluated for sleep apnea and periodic leg movements and were excluded if the apnea-hypopnea index was greater than 10 or the periodic limb movement arousal index was 10 or more events per hour. Additional PSG entry criteria were (1) latency to persistent sleep (LPS) ≥ 10 minutes for both screening nights; (2) mean WASO of ≥ 45 minutes, with neither night < 30 minutes; and (3) TST ≥ 240 and ≤ 390 minutes on both nights.
Experimental Procedures and Study Assessments
After meeting all study entry criteria, randomly assigned patients were scheduled for PSGs on 2 consecutive nights within 2 to 10 days of the second screening PSG. On each night, the study drug was administered 30 minutes prior to PSG start time.
Standard PSG techniques 12 were used, and scoring of the PSG recording was performed at a centralized site, according to standard criteria. 13 Self-reported sleep variables were assessed using a post-sleep questionnaire, completed 15 to 25 minutes after PSG termination.
The Digit Symbol Substitution Test 14 and sleepiness/alertness visual analog scale (0 mm = very sleepy, 100 mm = very alert) were both administered approximately 1 hour following each PSG. Patients recorded their "ability to function," "alertness," and "physical well-being during the day" by completing the Assessment of Daily Function questionnaire, comprising 3 visual analog scale ratings, at home on the evening prior to the second treatment night and on the following evening. Adverse events and vital signs were assessed throughout the study. Clinical laboratory tests, physical examination, and electrocardiograms were performed the day following the final PSG.
Statistical Analysis
For each patient, mean values for all variables from the 2 screening PSG visits were calculated and used as baseline values; means of variables from the 2 treatment PSG visits were also calculated for each patient. Change from baseline values were used in all analyses for PSG, self-report, Digit Symbol Substitution Test, and Assessment of Daily Function variables. If 1 of 2 measures was missing, the remaining value was used as the mean. Randomly assigned patients who had at least 1 baseline and 1 treatment PSG were included in the efficacy analysis. The primary efficacy variable was the change from baseline in PSG WASO following tiagabine or placebo. Other PSG measurements analyzed were LPS, TST, number of 30-second awakenings, minutes of sleep stages 1, 2, and 3+4 (i.e., SWS), and rapid eye movement (REM) sleep. Two additional variables were (1) sleep efficiency during sleep period time, which was calculated as TST divided by the sleep period, where sleep period time was time in bed minus the LPS; and (2) the ratio Stage 3+4 divided by Stage 1 + WASO. The latter ratio has previously been reported as a potential measure of sleep disruption, where an increase in value is indicative of less sleep disruption. 15 In addition, Pearson correlation coefficients were calculated between the SWS (PSG) and self-reported ratings of sleep depth and of sleep quality, using both absolute numbers and mean changes, for each patient group and across all patient groups.
Because study hypotheses addressed each dose of tiagabine compared with placebo, paired comparisons were the primary analyses and were performed using an analysis of covariance model, with treatment and center as factors, and baseline value as covariate. All paired comparison tests were 2-tailed, with α set at .05. Parametric analyses findings were corroborated with nonparametric analyses.
Safety analyses included all patients who received at least 1 dose of study medication. Adverse events were defined by Medical Dictionary for Regulatory Activities-preferred term. 16 The Cochran-Armitage trend test was used to determine if adverse events were dose-related.
RESULTS
Patients
A total of 822 patients were evaluated, and 590 were excluded primarily because of failure to meet entry criteria; 232 patients were randomly assigned (tiagabine: 4 mg, n = 46; 6 mg, n = 45; 8 mg, n = 45; 10 mg, n = 49; placebo, n = 47; Figure 1 ). All randomly assigned patients received at least 1 dose of study medica- tion and are included in the safety analyses. Table 1 contains demographic characteristics for each treatment group. Two patients receiving tiagabine 10 mg discontinued prior to the completion of the first randomization PSG because of adverse events (discussed below). The efficacy analysis, therefore, was performed on 230 patients with at least 1 postrandomization efficacy assessment. There were no significant differences among groups in any of the demographic characteristics.
PSG Variables
PSG variable means for each treatment group following tiagabine or placebo are presented in Table 2 . Change from baseline in minutes of WASO did not differ significantly between any tiagabine dose and placebo. The mean reduction from baseline in minutes of WASO with tiagabine ranged from 26.3 to 35.2, as compared with 31.7 with placebo. There also were no significant differences between any tiagabine dose and placebo in LPS and TST.
Significantly greater increases from baseline in minutes of SWS were found with the 3 higher doses of tiagabine, compared with placebo (p < .01 for all). The mean change from baseline in minutes of SWS for placebo was 10.5; whereas, for the 3 higher tiagabine doses, SWS increased by 31.7, 39.6, and 52.9 minutes, respectively. When analyzed by hour of the night (Figure 2 ), tiagabine 10 mg was associated with greater time spent in SWS, with all but the first hour being significantly greater than placebo (p < .05). Tiagabine 6 mg and 8 mg had significantly greater increases in Stage 3+4 sleep at 5 of the 8 hours of the night, in comparison with placebo. The ratio Stage 3+4/(Stage 1+WASO) was increased significantly more with tiagabine 8 mg and 10 mg than with placebo (p < .01).
All doses of tiagabine significantly reduced minutes of Stage 1 sleep relative to placebo (p < .01 for all). Mean decreases from baseline for ascending doses of tiagabine were -5.7, -7.1, -7.3, and -15.5 minutes, respectively; minutes of Stage 1 sleep increased 1.8 minutes in the placebo group. The change from baseline in minutes of REM sleep differed from placebo for all tiagabine doses (p < .05 for each). The mean change for placebo was 11.6 and, for ascending doses of tiagabine, was 3.6, 1.7, -2.1, and -9.9 minutes, respectively. REM latency did not differ from placebo for any tiagabine dose.
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Self-Report Variables
There were no consistent, drug-related improvements in selfreported ratings of sleep, compared with placebo (Table 3) . Estimates of TST, sleep depth and quality, and refreshing quality of sleep were found to be significantly less favorable with tiagabine 10 mg compared with placebo (p < .05). Notably, SWS changes were not correlated with either sleep depth (change from baseline ranging from -0.14 to 0.25) or sleep quality (change from baseline ranging from -0.12 to 0.13). Ability to concentrate or think clearly, level of alertness, and sense of physical well-being, as assessed by the Assessment of Daily Function, also did not differ between placebo and tiagabine 4, 6, or 8 mg. All 3 Assessment of Daily Function variables were significantly reduced with the 10-mg dose, as compared with placebo (p < .05).
Tolerability and Safety
Tiagabine 4 mg and 6 mg had a tolerability profile similar to that of placebo, with the exception of the incidence of headache, which was numerically greater with the 4-mg dose (9%) compared with placebo (4%; Table 4 ). In patients receiving tiagabine 8 mg and 10 mg, the most commonly reported adverse events were dizziness (11% and 18%, respectively, versus placebo, 2%) and nausea (7% and 14%, respectively, versus placebo, 0%). The Cochran-Armitage trend test showed a significant dose-related increase in the rate of anxiety (p = .024), dizziness (p = .002), and nausea (p = .002). No other adverse events were significantly associated with dose. A total of 6 patients receiving tiagabine discontinued because of 1 or more adverse events (10 mg, n = 5; 4 mg, n = 1). Dizziness (n = 4), anxiety (n = 3), and nausea (n = 2) were the most common adverse events leading to discontinuation. There were no clinically meaningful changes in laboratory values and vital signs for any patient in the study.
Mean number of correct responses on the Digit Symbol Substitution Test for each group were 4 mg, 59.1; 6 mg, 57.8; 8 mg, 60.7; 10 mg, 55.7; and placebo, 61.6. The 10-mg group, but not other doses, had significantly fewer mean number of correct responses on the Digit Symbol Substitution Test, compared with placebo. Mean visual analog scale values (lower = more sleepiness) for each group were 4 mg, 59.2; 6 mg, 64.2; 8 mg, 57.1; 10 mg, 52.2; placebo, 60.2. The 10-mg group, but not other doses, reported significantly more sleepiness on the visual analog scale in comparison with placebo.
DISCUSSION
The results of this randomized, double-blind, placebo-controlled study show that, relative to placebo, tiagabine 6, 8, and 10 mg significantly increased SWS, with a corresponding significant decrease in Stage 1 sleep at all tiagabine doses. The traditional hypnotic-efficacy variables of WASO, LPS, and TST were not affected by any tiagabine dose. Tiagabine 4 and 6 mg had a tolerability profile similar to that of placebo. The most commonly reported adverse events for tiagabine 8 and 10 mg were nausea and dizziness, which are commonly observed with tiagabine. 17 Tiagabine 10 mg differed from placebo on morning sedation. The findings of the present study are reasonably consistent with another study of primary insomniacs, 9 in which tiagabine significantly increased SWS and decreased Stage 1 sleep in a dose-dependent manner compared with placebo. In that investigation, doses of tiagabine up to 8 mg were found to be similar to placebo in tolerability profiles and psychomotor performance, again largely consistent with
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Data are presented as number (%) of adverse events (as defined by the Medical Dictionary for Regulatory Activities-preferred term) that occurred in ≥ 5% of patients in any treatment condition. *p < .05 vs placebo for dose-related increase in rate of incidence.
the current findings. In a small double-blind, placebo-controlled study of healthy elderly volunteers, tiagabine 5 mg significantly increased SWS, as well as significantly improved sleep efficiency compared with placebo. 8 Significant improvement in self-report measures of sleep have not been observed in any of these studies.
At present, the physiologic and/or clinical correlates of changes in SWS have not been established. However, it is interesting to consider the possibility that drugs that increase SWS, without strongly affecting traditional hypnotic efficacy measures (i.e., PSG and self-reported TST, LPS, etc.), may have a clinical or physiologic benefit. For example, individuals with paradoxical insomnia may benefit from changes in sleep other than increased sleep duration and more-rapid sleep onset. Individuals with chronic pain as a contributor to sleep disturbance may have fewer arousals and awakenings with enhanced SWS. Reduced SWS is a consistent finding in major depressive disorder, an illness for which insomnia is a very common comorbid condition. Clearly, studies in these types of populations would be interesting and of scientific value. On the other hand, the lack of benefit on selfreport measures in primary insomniacs may limit the usefulness of tiagabine, at least in primary insomnia. The lack of correlation between SWS and sleep depth and sleep quality highlights the lack of understanding of the physiologic processes underlying self-reported estimates of sleep.
There is a well-documented relation between time spent in SWS and arousability from sleep. The putative importance of SWS for restoration 18, 19 raises the hypothesis that tiagabine, or other drugs that significantly increase SWS, may positively affect sleep in some uncharacterized way. Further research should determine whether the effects on SWS persist beyond a few nights and if a qualitative difference in sleep can be shown beyond that attributable to increased sleep time seen with BzRA.
In conclusion, the results of this large-sample investigation show that, in adults with primary insomnia, tiagabine significantly increased SWS, with a corresponding significant decrease in Stage 1 sleep. However, the traditional hypnotic-efficacy variables of WASO, LPS, and TST were not affected by any dose of tiagabine. Moreover, the Food and Drug Administration has recently issued a statement emphasizing that the efficacy and safety of tiagabine have not yet been established for uses other than as an adjunctive anticonvulsant. Tiagabine was generally well tolerated, with the 4-mg and 6-mg doses having tolerability profiles similar to placebo, and was associated with more adverse events, psychomotor impairment, and negative self-reports about daytime function at 10 mg. Investigation into the clinical correlates of the effect of tiagabine on SWS is warranted at doses below 10 mg in adults.
